SCOUT-HCM findings show mavacamten significantly reduces Valsalva LVOT gradient in adolescents with symptomatic oHCM.
Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback